John Day, MD
Neuromuscular Medicine · Stanford, CANPI 1447291992
Payments from drug & device makers
Across 974 payments — averaging $14,782 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$7.1M
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$1.7M
- Hoffmann-la Roche Limited$1.5M
- Sarepta Therapeutics, Inc.$1.5M
- Sanofi$1.2M
- F. Hoffmann-la Roche AG$388K
- plus $890K from 14 others
Across 90 payments — averaging $434.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$30K
- Sanofi$8K
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$963
- Novartis$249
- Biogen$136
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 84 | $7,139,170 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 234 | $1,747,701 |
| Hoffmann-la Roche Limited | 102 | $1,516,703 |
| Sarepta Therapeutics, Inc. | 297 | $1,510,993 |
| Sanofi | 50 | $1,204,931 |
| F. Hoffmann-la Roche AG | 49 | $387,593 |
| Roche Products Limited | 31 | $328,607 |
| Novartis | 12 | $229,695 |
| PTC Therapeutics, Inc. | 63 | $165,153 |
| Ionis Pharmaceuticals, Inc. | 5 | $63,563 |
| Genentech, Inc. | 9 | $36,765 |
| Vertex | 4 | $24,015 |
| Genentech USA, Inc. | 16 | $19,012 |
| Insmed, Inc. | 7 | $6,442 |
| Sanofi US Services Inc. | 3 | $6,200 |
| Novartis Pharma AG | 1 | $3,362 |
| Biomarin Pharmaceutical Inc. | 4 | $2,798 |
| Merck | 1 | $2,640 |
| NS Pharma, Inc. | 1 | $1,326 |
| Argenx US, Inc. | 1 | $625 |
How this compares
$14,397,293 in reported general payments places this provider in the 95th percentile of 44 neuromuscular medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neuromuscular medicine in Stanford
- Jacinda SampsonStanford$377K
- Yuen SoStanford$77K
- Sarada SakamuriStanford$404
- Kathie LinStanford$214
- Maxwell GreeneStanford$111
- Kenneth LeungStanford$15
- Tahseen MozaffarOrange$3.2M
- Ali HabibOrange$1.6M
- Namita GoyalOrange$1.5M
- Jeffrey RosenfeldFresno$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.